Dataset Information


Oncogenic RAS primes primary acute myeloid leukemia blasts for differentiation

ABSTRACT: RAS mutations are frequently found among AML patients, generating a constitutively active signaling protein changing cellular proliferation, differentiation and apoptosis. We previously showed that treatment of AML patients with high-dose cytarabine (HDAC) is preferentially beneficial for those with an oncogenic RAS mutation. By applying a murine AML model, we could ascribe this effect to a RAS-driven, p53-dependent induction of differentiation. Here, we sought to confirm the correlation between RAS status and differentiation of blasts obtained from AML patients. The expression signature of primary AML blasts expressing oncogenic RAS where compared to blasts with wtRAS. Blasts where obtained from peripheral blood or bone marrow samples from patients with CBFbeta-MYH11 translocations and with or without an additional NRAS point mutation. As a reference, the Kasumi-1 acute myeloid leukemia cell line was used.

SUBMITTER: Kathleen Stabla   Cornelia Brendel   Petra Roth   Thomas Illmer   Marco Mernberger   Sabine Teichler   Axel Millahn   Andreas Neubauer   Christina Barckhausen   Thorsten Stiewe   Michael Krause  

PROVIDER: E-MTAB-2090 | ArrayExpress | 2015-11-20


Similar Datasets

2010-12-02 | GSE21107 | GEO
2010-12-02 | E-GEOD-21107 | ArrayExpress
2013-04-04 | E-GEOD-38865 | ArrayExpress
2009-12-29 | GSE19681 | GEO
2014-05-01 | E-GEOD-55519 | ArrayExpress
2010-12-10 | E-GEOD-21495 | ArrayExpress
| GSE9476 | GEO
2012-04-16 | E-GEOD-37307 | ArrayExpress
2014-01-01 | E-GEOD-52541 | ArrayExpress
2008-06-16 | E-GEOD-9476 | ArrayExpress